Company Quick10K Filing
Quick10K
Medifast
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$142.96 12 $1,700
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2019-06-12 Amend Bylaw, Shareholder Vote, Other Events, Exhibits
8-K 2019-05-01 Earnings, Exhibits
8-K 2019-03-13 Other Events, Exhibits
8-K 2019-01-14 Regulation FD, Exhibits
8-K 2018-12-11 Other Events, Exhibits
8-K 2018-11-06 Earnings, Exhibits
8-K 2018-09-06 Other Events, Exhibits
8-K 2018-08-02 Earnings, Exhibits
8-K 2018-07-24 Regulation FD, Exhibits
8-K 2018-06-15 Regulation FD
8-K 2018-06-14 Other Events, Exhibits
8-K 2018-06-13 Shareholder Vote
8-K 2018-05-03 Earnings, Exhibits
8-K 2018-03-15 Other Events, Exhibits
8-K 2018-03-06 Earnings, Officers, Exhibits
8-K 2018-02-28 Other Events, Exhibits
8-K 2018-01-09 Regulation FD, Exhibits
DIS Walt Disney 240,140
MPW Medical Properties Trust 6,900
IBOC International Bancshares 2,680
FF Futurefuel 608
NODK NI Holdings 377
KFFB Kentucky First Federal Bancorp 63
MSVB Mid-Southern Bancorp 45
FVE Five Star Senior Living 30
MKRS Mikros Systems 0
RBOI Results Based Outsourcing 0
MED 2019-03-31
Item 2. Management’S Discussion and Analysis of Financial Condition and Results of Operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures
Part II Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 6. Exhibits
EX-31.1 med-20190331ex311afd375.htm
EX-31.2 med-20190331ex3120f9534.htm
EX-32.1 med-20190331ex321896b71.htm

Medifast Earnings 2019-03-31

MED 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 med-20190331x10q.htm 10-Q med_Current_Folio_10Q

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

WASHINGTON, D.C. 20549

 

FORM 10‑Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2019

 

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                  to                    .

 

Commission File Number:  001‑31573

 

Medifast, Inc.

 

(Exact name of registrant as specified in its charter)

 

 

 

 

Delaware

    

13‑3714405

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

100 International Drive

Baltimore, Maryland 21202

Telephone Number: (410) 581‑8042

 

(Address of Principal Executive Offices, Zip Code and Telephone Number, Including Area Code)

 

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

 

Yes   No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 

 

Yes   No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

 

 

 

 

 

Large accelerated filer ☒

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☐

Emerging growth company☐

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). 

 

Yes   No 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

Title of each class:

    

Trading Symbol

    

Name of each exchange on which registered:

Common Stock, par value $0.001 per share

 

MED

 

NYSE

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

The number of shares of the registrant’s common stock outstanding at April 22, 2019 was 11,897,679.

 

 

 

 


 

 

 

Medifast, Inc. and subsidiaries

Index

 

 

 

Part 1 – Financial Information:

    

 

 

 

 

Item 1 – Financial Statements

 

 

 

 

 

Condensed Consolidated Statements of Income (unaudited) for the Three Months Ended March 31, 2019 and 2018 

 

2

 

 

 

Condensed Consolidated Statements of Comprehensive Income (unaudited) for the Three Months Ended March 31, 2019 and 2018 

 

3

 

 

 

Condensed Consolidated Balance Sheets (unaudited) as of March 31, 2019 and December 31, 2018 

 

4

 

 

 

Condensed Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2019 and 2018 

 

5

 

 

 

Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited) for the Three Months Ended March 31, 2019 and 2018 

 

6

 

 

 

Notes to Condensed Consolidated Financial Statements (unaudited) 

 

7

 

 

 

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations 

 

14

 

 

 

Item 3 – Quantitative and Qualitative Disclosures about Market Risk 

 

18

 

 

 

Item 4 – Controls and Procedures 

 

18

 

 

 

Part II – Other Information 

 

 

 

 

 

Item 1 – Legal Proceedings 

 

19

 

 

 

Item 1A – Risk Factors 

 

19

 

 

 

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 

 

19

 

 

 

Item 6 – Exhibits 

 

20

 

 

1


 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(in thousands, except per share amounts & dividend data)

 

 

 

 

 

 

 

 

 

 

Three months ended March 31,

 

 

 

2019

 

2018

 

 

 

 

 

 

 

 

 

Revenue

 

$

165,876

 

$

98,596

 

Cost of sales

 

 

40,729

 

 

23,788

 

Gross profit

 

 

125,147

 

 

74,808

 

 

 

 

 

 

 

 

 

Selling, general, and administrative

 

 

100,432

 

 

60,125

 

 

 

 

 

 

 

 

 

Income from operations

 

 

24,715

 

 

14,683

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

Interest income, net

 

 

312

 

 

249

 

Other income (expense)

 

 

(6)

 

 

(1)

 

 

 

 

306

 

 

248

 

 

 

 

 

 

 

 

 

Income from operations before income taxes

 

 

25,021

 

 

14,931

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

4,271

 

 

2,709

 

 

 

 

 

 

 

 

 

Net income

 

$

20,750

 

$

12,222

 

 

 

 

 

 

 

 

 

Earnings per share - basic

 

$

1.75

 

$

1.02

 

 

 

 

 

 

 

 

 

Earnings per share - diluted

 

$

1.70

 

$

1.01

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding -

 

 

 

 

 

 

 

Basic

 

 

11,880

 

 

12,030

 

Diluted

 

 

12,240

 

 

12,139

 

 

 

 

 

 

 

 

 

Cash dividends declared per share

 

$

0.75

 

$

0.48

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2


 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(in thousands)

 

 

 

 

 

 

 

 

 

Three months ended March 31,

 

 

2019

 

2018

 

 

 

 

 

 

 

Net income

 

$

20,750

 

$

12,222

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

Foreign currency translation

 

 

 1

 

 

 -

Unrealized gains (losses) on marketable securities

 

 

126

 

 

(84)

 

 

 

 

 

 

 

Other comprehensive income (loss)

 

 

127

 

 

(84)

 

 

 

 

 

 

 

Comprehensive income

 

$

20,877

 

$

12,138

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in thousands, except par value)

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

 

December 31,

 

 

 

 

2019

 

 

2018

 

 

 

 

 

 

 

 

ASSETS

Current Assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

$

101,842

 

$

81,364

Accounts receivable-net of doubtful accounts of $270 and $394 at

 

 

 

 

 

 

 

March 31, 2019 and December 31, 2018, respectively

 

 

 

631

 

 

1,011

Inventory

 

 

 

43,257

 

 

38,888

Investment securities

 

 

 

18,585

 

 

19,670

Prepaid expenses and other current assets

 

 

 

4,995

 

 

4,586

Total current assets

 

 

 

169,310

 

 

145,519

 

 

 

 

 

 

 

 

Property, plant and equipment - net

 

 

 

23,343

 

 

19,747

Right-of-use asset

 

 

 

12,864

 

 

 -

Other assets

 

 

 

941

 

 

1,183

Deferred tax assets

 

 

 

3,612

 

 

2,980

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

 

$

210,070

 

$

169,429

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

 

$

74,452

 

$

60,323

Current lease obligation

 

 

 

2,443

 

 

 -

Total current liabilities

 

 

 

76,895

 

 

60,323

 

 

 

 

 

 

 

 

Lease obligation, less current lease obligation

 

 

 

11,107

 

 

 -

Total liabilities

 

 

 

88,002

 

 

60,323

 

 

 

 

 

 

 

 

Stockholders' Equity

 

 

 

 

 

 

 

Common stock, par value $.001 per share: 20,000 shares authorized;

 

 

 

 

 

 

 

12,126 and 12,117 issued and 11,898 and 11,868 outstanding

 

 

 

 

 

 

 

at March 31, 2019 and December 31, 2018, respectively

 

 

 

12

 

 

12

Additional paid-in capital

 

 

 

9,805

 

 

8,802

Accumulated other comprehensive loss

 

 

 

(46)

 

 

(173)

Retained earnings

 

 

 

143,176

 

 

131,344

Less: Treasury stock at cost, 193 shares at March 31, 2019 and December 31, 2018, respectively

 

 

 

(30,879)

 

 

(30,879)

Total stockholders' equity

 

 

 

122,068

 

 

109,106

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

$

210,070

 

$

169,429

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4


 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(in thousands)

 

 

 

 

 

 

 

 

 

 

Three months ended March 31,

 

 

 

2019

 

2018

 

 

 

 

 

 

 

 

 

Operating Activities

 

 

 

 

 

 

 

Net income

 

$

20,750

 

$

12,222

 

Adjustments to reconcile net income to cash provided by operating activities

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,067

 

 

1,544

 

Share-based compensation

 

 

990

 

 

805

 

Loss on sale of disposal of property, plant and equipment

 

 

 -

 

 

214

 

Realized loss on investment securities, net

 

 

82

 

 

57

 

Amortization of premium on investment securities

 

 

129

 

 

153

 

Deferred income taxes

 

 

(632)

 

 

(105)

 

Change in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

 

380

 

 

108

 

Inventory

 

 

(4,369)

 

 

2,942

 

Income taxes, prepaid

 

 

 -

 

 

2,738

 

Prepaid expenses and other current assets

 

 

(409)

 

 

727

 

Other assets

 

 

23

 

 

(1)

 

Accounts payable and accrued expenses

 

 

14,723

 

 

(3,396)

 

Net cash flow provided by operating activities

 

 

32,734

 

 

18,008

 

 

 

 

 

 

 

 

 

Investing Activities

 

 

 

 

 

 

 

Sale and maturities of investment securities

 

 

1,000

 

 

1,200

 

Purchase of property and equipment

 

 

(4,444)

 

 

(1,286)

 

Net cash flow used in investing activities

 

 

(3,444)

 

 

(86)

 

 

 

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

 

 

Options exercised by executives and directors

 

 

269

 

 

62

 

Net shares repurchased for employee taxes

 

 

(256)

 

 

(215)

 

Cash dividends paid to stockholders

 

 

(8,826)

 

 

(5,883)

 

Net cash flow used in financing activities

 

 

(8,813)

 

 

(6,036)

 

 

 

 

 

 

 

 

 

Foreign currency impact

 

 

 1

 

 

 -

 

 

 

 

 

 

 

 

 

Increase in cash and cash equivalents

 

 

20,478

 

 

11,886

 

Cash and cash equivalents - beginning of the period

 

 

81,364

 

 

75,077

 

Cash and cash equivalents - end of period

 

$

101,842

 

$

86,963

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

Income taxes received

 

$

24

 

$

 -

 

Dividends declared included in accounts payable

 

$

9,229

 

$

5,943

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2019

 

 

Number of Shares Issued

 

 

Common Stock

 

 

Additional Paid-In Capital

 

 

Accumulated Other Comprehensive Loss

 

 

Retained Earnings

 

 

Treasury Stock

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2018

 

12,117

 

$

12

 

$

8,802

 

$

(173)

 

$

131,344

 

$

(30,879)

 

$

109,106

Net income

 

 -

 

 

 -

 

 

 -

 

 

 -

 

 

20,750

 

 

 -

 

 

20,750

Share-based compensation

 

 -

 

 

 -

 

 

990

 

 

 -

 

 

 -

 

 

 -

 

 

990

Options exercised by executives and directors

 

10

 

 

 -

 

 

269

 

 

 -

 

 

 -

 

 

 -

 

 

269

Net shares repurchased for employee taxes

 

(1)

 

 

 -

 

 

(256)

 

 

 -

 

 

 -

 

 

 -

 

 

(256)

Other comprehensive income

 

 -

 

 

 -

 

 

 -

 

 

127

 

 

 -

 

 

 -

 

 

127

Cash dividends declared to stockholders

 

 -

 

 

 -

 

 

 -

 

 

 -

 

 

(8,918)

 

 

 -

 

 

(8,918)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2019

 

12,126

 

$

12

 

$

9,805

 

$

(46)

 

$

143,176

 

$

(30,879)

 

$

122,068

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2018

Balance, January 1, 2018, as reported

 

12,103

 

$

12

 

$

4,967

 

$

(160)

 

$

103,762

 

$

 -

 

$

108,581

Cumulative effect adjustments from changes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

in accounting standards

 

 -

 

 

 -

 

 

 -

 

 

 -

 

 

(2,018)

 

 

 -

 

 

(2,018)

Balance January 1, 2018, as adjusted

 

12,103

 

 

12

 

 

4,967

 

 

(160)

 

 

101,744

 

 

 -

 

 

106,563

Net income

 

 -

 

 

 -

 

 

 -

 

 

 -

 

 

12,222

 

 

 -

 

 

12,222

Share-based compensation

 

16

 

 

 -

 

 

805

 

 

 -

 

 

 -

 

 

 -

 

 

805

Options exercised by executives and directors

 

14

 

 

 -

 

 

62

 

 

 -

 

 

 -

 

 

 -

 

 

62

Net shares repurchased for employee taxes

 

(3)

 

 

 -

 

 

(215)

 

 

 -

 

 

 -

 

 

 -

 

 

(215)

Treasury stock from cashless options

 

 9

 

 

 -

 

 

750

 

 

 -

 

 

 -

 

 

(750)

 

 

 -

Other comprehensive loss

 

 -

 

 

 -

 

 

 -

 

 

(84)

 

 

 -

 

 

 -

 

 

(84)

Cash dividends declared to stockholders

 

 -

 

 

 -

 

 

 -

 

 

 -

 

 

(5,723)

 

 

 -

 

 

(5,723)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2018

 

12,139

 

$

12

 

$

6,369

 

$

(244)

 

$

108,243

 

$

(750)

 

$

113,630

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


 

 

MEDIFAST, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).  Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted.  However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading.  The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date.

The results of operations for the three months ended March 31,  2019 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2019.  The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the 2018 audited consolidated financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2018 (“2018 Form 10-K”).

Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Medifast, Inc. and its wholly-owned subsidiaries.  All significant intercompany accounts and transactions have been eliminated.

Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.

Accounting Pronouncements Adopted in 2019 – In February 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220) to address a specific consequence of the Tax Cuts and Jobs Act (“TCJA”) by allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the TCJA’s reduction of the U.S. federal corporate income tax rate. This ASU is effective for all entities for annual periods beginning after December 15, 2018, with early adoption permitted, and is to be applied either in the period of adoption or retrospectively to each period in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized.  The Company adopted this ASU in the first quarter of 2019.  There was no material impact on the Company's condensed consolidated results of operations or cash flows. The Company's policy for releasing disproportionate income tax effects from accumulated other comprehensive income utilizes the portfolio approach.   

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires an entity to recognize a right-of-use asset (“ROU”) asset and a lease liability on the balance sheet for all leases, including operating leases, and also requires disclosures about the amount, timing and uncertainty of cash flows arising from leases.  Subsequent to the issuance of Topic 842, the FASB clarified the guidance through several ASUs; hereinafter the collection of lease guidance is referred to as “ASC 842”.

On January 1, 2019, the Company adopted ASC 842 using the modified retrospective method for all lease arrangements at the beginning of the period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be reported in accordance with the Company’s historic accounting under ASC 840, Leases. The standard had a material impact on the Company’s Consolidated Condensed Balance Sheets, but did not have a significant impact on the Company’s consolidated net earnings and cash

7


 

flows. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases. For leases that commenced before the effective date of ASC 842, the Company elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases. The Company also elected to exclude leases with a term of 12 months or less in the recognized ROU assets and lease liabilities.

As a result of the cumulative impact of adopting ASC 842, the Company recorded ROU assets of $11.9 million, net of $686 thousand of accrued rent, and lease liabilities of $12.6 million as of January 1, 2019, primarily related to office and warehouse space and certain equipment, based on the present value of the future lease payments on the date of adoption.

The Company determines if an arrangement is a lease at inception. The ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any prepaid lease payments and lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense.    See Note 5 “LEASES” for additional information about this adoption.

 

2. INVENTORIES

Inventories consist principally of packaged meal replacements held in the Company’s warehouses.   Inventory is stated at the lower of cost or net realizable value, utilizing the first-in, first-out method.  The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs.  On a quarterly basis, management reviews inventory for unsalable or obsolete inventory.

Inventories consisted of the following (in thousands):

 

 

 

 

 

 

 

 

 

March 31, 2019

 

December 31, 2018

 

 

 

 

 

 

 

Raw materials

 

$

10,535

 

$

11,156

Packaging

 

 

1,813

 

 

1,563

Non-food finished goods

 

 

4,078

 

 

2,391

Finished goods

 

 

28,739

 

 

25,509

Reserve for obsolete inventory

 

 

(1,908)

 

 

(1,731)

Total

 

$

43,257

 

$

38,888

 

 

 

3. EARNINGS PER SHARE

Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of the Company’s common stock outstanding during the periods presented.  Diluted EPS is calculated utilizing the weighted average number of shares of the Company’s common stock outstanding adjusted for the effect of dilutive common stock equivalents.

8


 

The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):

 

 

 

 

 

 

 

 

 

Three months ended March 31,

 

 

2019

 

2018

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

Net income

 

$

20,750

 

$

12,222

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

Weighted average shares of common stock outstanding

 

 

11,880

 

 

12,030

Effect of dilutive common stock equivalents

 

 

360

 

 

109

Weighted average shares of common stock outstanding

 

 

12,240

 

 

12,139

 

 

 

 

 

 

 

Earnings per share - basic

 

$

1.75

 

$

1.02

 

 

 

 

 

 

 

Earnings per share - diluted

 

$

1.70

 

$

1.01

 

The calculation of diluted EPS excluded 826 and 4,690 antidilutive options outstanding for the three months ended March 31, 2019 and 2018, respectively. The calculation for diluted EPS for the three months ended, March 31, 2019 and 2018 also excluded 1,198 and 0 antidilutive restricted stock awards, respectively.  EPS is computed independently for each of the quarters presented; accordingly, the sum of the quarterly earnings per common share may not equal the year-to-date total computed.

4. SHARE-BASED COMPENSATION

Stock Options:

The Company has issued non-qualified and incentive stock options to employees and nonemployee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company’s common stock, and dividend yield. Options outstanding as of March 31, 2019 generally vest over a period of three years and expire ten years from the date of grant. The exercise price of these options ranges from $26.52 to $171.68. Due to the Company’s lack of option exercise history, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility is based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. For the three months, ended March 31, 2019, the Company did not grant stock options.  For the three months ended March 31, 2018, the weighted average input assumptions used were as follows:

 

 

 

2018

Expected term (in years)

6.4

Risk-free interest rate

2.64%

Expected volatility

33.31%

Dividend yield

2.88%

9


 

The following table is a summary of our stock option activity:

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31,

 

 

2019

 

2018

 

 

Shares

 

Weighted-Average Exercise Price

 

Shares

 

Weighted-Average Exercise Price

 

(shares in thousands)

 

 

 

 

 

 

 

 

 

 

Outstanding at beginning of period

107

 

$

49.26

 

106

 

$

31.18

 

Granted

 -

 

 

 -

 

51

 

 

66.68

 

Exercised

(10)

 

 

27.86

 

(21)

 

 

28.87

 

Outstanding at end of the period

97

 

$

52.51

 

136

 

$

44.79

 

Exercisable at end of the period

53

 

$

40.97

 

60

 

$

29.94

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of March 31, 2019, the weighted-average remaining contractual life was 7.86 years with an aggregate intrinsic value of $7.4 million for outstanding stock options and the weighted-average remaining contractual life was 7.10 years with an aggregate intrinsic value of $4.6 million for exercisable options. For the three months, ended March 31, 2019, the Company did not grant stock options.  The weighted-average grant date fair value of options granted during the three months ended March 31, 2018 was $17.79. The unrecognized compensation expense calculated under the fair value method for shares expected to vest as of March 31, 2019 was $0.8 million and is expected to be recognized over a weighted average period of 3.10 years. The Company received $269 thousand and $62 thousand in cash proceeds from the exercise of stock options during the three months ended March 31, 2019 and 2018, respectively. Upon exercising of options, the Company withheld shares for employee taxes of 1 thousand and 3 thousand for the three months ended March 31, 2019 and 2018, respectively. The total intrinsic value for stock options exercised during the three months ended March 31, 2019 and 2018 was $1.0 million and $1.4 million, respectively.

Restricted Stock:

The Company has issued restricted stock to employees and nonemployee directors generally with vesting terms up to five years after the date of grant.  The fair value of the restricted stock is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.  The following table summarizes our restricted stock activity:

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31,

 

2019

 

2018

 

Shares

 

Weighted-Average Grant Date Fair Value

 

Shares

 

Weighted-Average Grant Date Fair Value

(shares in thousands)

 

 

 

 

 

 

 

 

 

Outstanding at beginning of period

57

 

$

50.55

 

129

 

$

32.15

Granted

27

 

 

130.59

 

16

 

 

66.68

Vested

(21)

 

 

33.92

 

(69)

 

 

28.35

Outstanding at end of the period

63

 

$

90.60

 

76

 

$

42.99

 

The total fair value of restricted stock awards vested during the three months ended March 31, 2019 and 2018 was $2.8 million and $4.8 million, respectively.

The total share-based compensation charged against income was $990 thousand and $805 thousand during the three months ended March 31, 2019 and 2018, respectively. The total costs of the options and restricted stock awards charged against income was $672 thousand and $580 thousand during the three months ended March 31, 2019 and 2018, respectively. Also included for the three months ended March 31, 2019 and 2018 was $76 thousand and $73 thousand, respectively, for 63,300 performance-based contingent shares for certain key executives. Included for the three months ended March 31, 2019 and 2018 was $152 thousand in expense for 210,000 performance-based contingent shares granted to our CEO that will vest based on the achievement of certain Company performance targets.  Included for the

10


 

three months ended March 31, 2019 was $90 thousand for 19,244 performance-based contingent shares for certain key executives.

The total income tax benefit recognized in the Condensed Consolidated Statements of Income for restricted stock awards was $833 thousand and $917 thousand for the three months ended March 31, 2019 and 2018, respectively.

There was $4.9 million of total unrecognized compensation cost related to restricted stock awards as of March 31, 2019, which is expected to be recognized over a weighted-average period of 2.28 years. There was $3.1 million of unrecognized compensation cost related to the 292,544 performance based contingent shares discussed above as of March 31, 2019, which is expected to be recognized over a weighted-average period of 2.42 years.

5. LEASES

The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company’s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases as of March 31, 2019 and for the three-month period then ended.

Our leases relating to office and warehouse space have terms of 63 months to 122 months. Our leases relating to equipment have lease terms of 60 to 203 months, with some of them having clauses relating to automatic renewal. 

The Company’s warehouse agreement also contains non-lease components, in the form of payments towards logistics services and labor charges which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but will be recognized as expense when they are incurred.

For the three months ended March 31, 2019, the operating lease expense was $662 thousand.

Supplemental cash flow information related to the Company’s operating leases were as follows (in thousands):

 

 

 

 

 

 

Three months ended March 31,

 

 

2019

 

 

 

 

Cash paid for amounts included in the measurements of lease liabilities

 

 

 

Operating cash flow from operating leases

 

$

663

 

 

 

 

Right-of-use assets obtained in exchange for lease obligations

 

 

 

Operating leases

 

$

1,490

 

 

 

 

As of March 31, 2019, the weighted average remaining lease term was 5.5 years and the weighted average discount rate was 3.9%.

The following table presents the maturity of the Company’s operating lease liabilities as of March 31, 2019 (in thousands):

 

 

 

 

2019 (excluding the three months ended March 31, 2019)

 

$

2,191

2020

 

 

2,951

2021

 

 

2,985

2022

 

 

2,641

2023

 

 

1,633

Thereafter

 

 

2,685

Total lease payments

 

$

15,086

Less: imputed interest

 

 

(1,536)

Total

 

$

13,550

 

 

 

 

11


 

As previously disclosed in our 2018 Form 10-K and under the previous lease accounting standard, future minimum lease commitments under non-cancelable operating leases with terms in excess of one year would have been as follows (in thousands):

 

 

 

 

 

 

 

2019

 

$

1,496

2020

 

 

1,528

2021

 

 

1,562

2022

 

 

1,222

2023

 

 

1,155

Thereafter

 

 

2,582

Total minimum lease payments

 

$

9,545

 

 

6. ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table sets forth the components of accumulated other comprehensive income (loss), net of tax where applicable (in thousands):

 

 

 

 

 

 

 

 

 

March 31, 2019

 

December 31, 2018

 

 

 

 

 

 

 

Foreign currency translation

 

$

(1)

 

$

(2)

Unrealized losses on marketable securities

 

 

(45)

 

 

(171)

Accumulated other comprehensive loss

 

$

(46)

 

$

(173)

 

 

 

7.  FINANCIAL INSTRUMENTS

Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.

12


 

The following tables represent cash and the available-for-sale securities adjusted cost, gross unrealized losses and fair value by significant investment category recorded as cash and cash equivalents or investment securities (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2019

 

 

 

Cost

 

 

Unrealized Losses

 

 

Accrued Interest

 

 

Estimated Fair Value

 

 

Cash & Cash Equivalents

 

 

Investment Securities